Navigation Links
Medical University of South Carolina Leads Multicenter Study Evaluating Biliary Sphincter Disorder
Date:9/26/2007

$6 Million Grant Funded by NIDDK

CHARLESTON, S.C., Sept. 26 /PRNewswire/ -- The Medical University of South Carolina (MUSC) will lead a $6 million study to determine the best techniques for diagnosing and treating sphincter of Oddi dysfunction (SOD), a painful condition that causes narrowing or spasm of the muscle that controls the flow of bile and pancreatic juice into the small intestine.

The national principal investigator for this five-year, multicenter, research project is Peter Cotton, MD, professor of medicine-gastroenterology and hepatology and founder of the Digestive Disease Center at MUSC.

The study, called Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD), is funded by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health and involves five other major research sites.

More than half a million patients undergo surgical removal of the gallbladder (cholecystectomy) annually in the United States, predominantly for gallbladder disease. Although most operations are successful, 10 to 20 percent of patients report persistent episodes of pain after surgery.

Some of these patients are found to have new gallstones, or other conditions such as pancreatitis. When these causes are excluded, SOD is suspected. Dysfunction of the sphincter (narrowing or spasm) can cause back pressure in the liver or pancreas, resulting in severe attacks of pain and significant interference with daily living.

The focus of this study is to clarify how best to detect and exclude SOD, and how best to treat it. Currently, patients with suspected SOD are usually referred to special centers, including those involved in the study, and undergo multiple tests.

The standard treatment is endoscopic retrograde cholangiopancreatography (ERCP), which allows complete documentation of the relevant anatomy, assessment of any sphincter spasm by measuring the pressure with manometry, and immediate treatment by cutting the sphincter (sphincterotomy).

This process has not been subjected to controlled scientific trial, which is deemed necessary for two reasons: Only about 60 percent of these patients experience lasting relief, and both ERCP and sphincterotomy carry significant risks.

EPISOD is aimed at determining the best candidates for treatment by analyzing the patients' characteristics (pain patterns, presence of other digestive function disorders and psychological factors), measuring the sphincter pressures at ERCP and allocating treatment to sphincterotomy or control. Study participants will be followed for at least one year to assess their outcomes and need for further treatment.

Results of the EPISOD trial should provide patients and practitioners with the scientific evidence to more effectively and safely treat patients with suspected SOD.

Dr. Cotton's colleagues on this study include researchers from MUSC; the University of North Carolina; the University of Michigan; Johns Hopkins University; Indiana University; the University of Alabama; Virginia Mason Medical Center, Seattle; and the University of Minnesota, Minneapolis.


'/>"/>
SOURCE Medical University of South Carolina
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... The ... the 2017 Public Leadership in Neurology Award (PLINA). The couple joins a prestigious ... Bruschi, Vice President Walter Mondale, actor Michael J. Fox and former U.S. Attorney ...
(Date:4/27/2017)... ... ... Are you investing in the safety of your friends and family? Each ... While most of us assume this type of accident will never happen to us, ... taking the time to learn how to respond effectively or prevent these accidents from ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: